Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants